glp-1 therapy for weight loss Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns A clinician's perspective 📝 GLP-1

Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis

The initial GAMT deficient patient experienced severe psychomotor impairment, refractory epilepsy, and movement disorder

OS, overall survival

Maiti A, DiNardo CD, Wang S, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger J, Thompson PA, Verstovsek S, Sasaki K, Andreeff M , Rausch CR, Montalbano KS, Pierce S, Kantarjian HM, Konopleva MY, Ravandi F

Eli Lilly's obesity pill, orforglipron, had a 12.4% average weight loss at its highest dose over 72 weeks, which means it's less effective than injections on the market

The Nrf2 in the pathophysiology of the intestine: molecular mechanisms and therapeutic implications for inflammatory bowel diseases